Kura Oncology Inc (KURA) is on track for its highest settlement since January
What a day it's been for
Kura Oncology Inc (NASDAQ:KURA). Shares of the drugmaker have exploded to a nearly 32% lead at $5.75, on the back of a
narrower-than-expected quarterly loss and upbeat drug data. Specifically, a mid-stage trial revealed KURA's cancer treatment tipifarnib produced "positive clinical activity, including objective responses."
Suffice it to say, a recent crop of bearish bettors may be left kicking rocks. Specifically,
short interest nearly doubled during the most recent reporting period -- and is now docked at a record high. A capitulation among these skeptics could further fuel KURA's run higher.
Meanwhile,
analyst optimism is being vindicated. Both of the brokerage firms tracking KURA rate it a "strong buy." Plus, the stock's consensus 12-month price target of $16.25 almost triples current levels, and sits in territory not charted since early November.
Despite being on pace for its highest daily finish since January, Kura Oncology Inc (NASDAQ:KURA) remains a long-term laggard. Since topping out at a record $25, the stock has lost more than three-quarters of its value.
Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.